Immunogenicity of Mycobacterium leprae unique antigens in leprosy endemic populations in Asia and Africa

Leprosy Review

Volumn 82, Issue 4, 2011, Pages 445-458

  Bobosha, Kidist ^a,b   van der Ploeg Van Schip, Jolien J ^a   Zewdie, Martha ^b   Sapkota, Bishwa Raj ^c   Hagge, Deanna A ^c   Franken, Kees L M C ^a   Inbiale, Wondmagegn ^b   Aseffa, Abraham ^b   Ottenhoff, Tom H M ^a   Geluk, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b All Africa Leprosy Tuberculosis and Rehabilitation Training Centre Addis Ababa   (Ethiopia)

^c Anandaban Leprosy Hospital   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; GAMMA INTERFERON; MYCOBACTERIUM LEPRAE ANTIGEN; PROTEIN ML0576; PROTEIN ML1989; PROTEIN ML1990; PROTEIN ML2283; PROTEIN ML2567; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BLOOD ANALYSIS; BORDERLINE BORDERLINE LEPROSY; BORDERLINE LEPROMATOUS LEPROSY; BORDERLINE TUBERCULOID LEPROSY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EARLY DIAGNOSIS; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHIOPIA; HIGH RISK POPULATION; HOUSEHOLD; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEPROSY; LYMPHOCYTE TRANSFORMATION TEST; MAJOR CLINICAL STUDY; NEPAL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; TUBERCULOID LEPROSY; TUBERCULOSIS;

ADULT; AFRICA; ANTIGENS, BACTERIAL; ASIA; BACTERIAL PROTEINS; ENDEMIC DISEASES; FEMALE; HUMANS; INTERFERON-GAMMA; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE;

EID: 84855869833     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Richardus JH, Habbema JD. The impact of leprosy control on the transmission of M. leprae: is elimination being attained? Lepr Rev, 2007; 78: 330-337.
2. Global leprosy situation, 2010. Wkly. Epidemiol. Rec. 85: 337-348.
3. Dockrell HM, Brahmbhatt S, Robertson BD et al. Diagnostic assays for leprosy based on T-cell epitopes. Lepr Rev, 2000; 71(Suppl): S55-S58.
4. Meima A, Van Veen NH, Richardus JH. Future prevalence of WHO grade 2 impairment in relation to incidence trends in leprosy: an exploration. Trop Med Int Health, 2008; 13: 241-246.
5. Scollard DM, Adams LB, Gillis TP et al. The continuing challenges of leprosy. Clin Microbiol Rev, 2006; 19: 338-381.
6. Cross H, Choudhary R. STEP: an intervention to address the issue of stigma related to leprosy in Southern Nepal. Lepr Rev, 2005; 76: 316-324.
7. Jacob JT, Franco-Paredes C. The stigmatization of leprosy in India and its impact on future approaches to elimination and control. PLoS Negl Trop Dis, 2008; 2: e113.
8. Leekassa R, Bizuneh E, Alem A. Prevalence of mental distress in the outpatient clinic of a specialized leprosy hospital. Addis Ababa, Ethiopia, 2002. Lepr Rev, 2004; 75: 367-375.
9. Rafferty J. Curing the stigma of leprosy. Lepr Rev, 2005; 76: 119-126.
10. Tsutsumi A, Izutsu T, Kramul Islam MD et al. Depressive status of leprosy patients in Bangladesh: association with self-perception of stigma. Lepr Rev, 2004; 75: 57-66.
11. Geluk A, Klein MR, Franken KL et al. Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. Infect Immun, 2005; 73: 5636-5644.
12. Geluk A, Spencer JS, Bobosha K et al. From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol, 2009; 16: 352-359.
13. Geluk A, van der PJ, Teles RO et al. Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection. Clin Vaccine Immunol, 2008; 15: 522-533.
14. Spencer JS, Dockrell HM, Kim HJ et al. Identification of specific proteins and peptides in Mycobacterium leprae suitable for the selective diagnosis of leprosy. J Immunol, 2005; 175: 7930-7938.
15. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
16. Oskam L, Slim E, Buhrer-Sekula S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. Lepr Rev, 2003; 74: 196-205.
17. Duthie MS, Goto E, Ireton GC et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol, 2007; 14: 1400-1408.
18. Geluk A, van der Ploeg-van Schip JJ, van Meijgaarden KE et al. Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays. Clin Vaccine Immunol, 2010; 17: 993-1004.
19. Aabye MG, Ravn P, Johansen IS et al. Incubation of whole blood at 39 degrees C augments gamma interferon (IFN-gamma)-induced protein 10 and IFN-gamma responses to Mycobacterium tuberculosis antigens. Clin Vaccine Immunol, 2011; 18: 1150-1156.
20. Franken KL, Hiemstra HS, van Meijgaarden KE et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif, 2000; 18: 95-99.
21. Dockrell HM, Black GF, Weir RE, Fine PE. Whole blood assays for interferon-gamma: practicalities and potential for use as diagnostic tests in the field. Lepr Rev, 2000; 71(Suppl): S60-S62.